Patents by Inventor Dennis J. Chute

Dennis J. Chute has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110091426
    Abstract: A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34+CD38? cells consistent with the PMVEC system is disclosed. HUBEC were isolated from cadaveric donors, passed in primary culture, cloned and found to be Von Willebrand Factor positive. Cultivation of purified bone marrow CD34+ cells on HUBEC monolayers supplemented with GM-CSF+IL-3+IL-6+SCF+flt-3 ligand caused a 14.5-fold increase in total cells, an 6.6-fold increase in CD34+ cells, and, most remarkably, a 440-fold increase in CD34+CD38? cells after 7 days. Further, CFU-GM production increased 15.1-fold, BFU-E increased 8-fold, and CFU-Mix increased 5.2-fold. Optimal generation was dependent upon the continued presence of exogenous supplied cytokines. In comparison, identically treated stroma-free suspension cultures supported a 10.2-fold expansion of total cells, a 3-fold increase in CD34+ cells and maintained the CD34+CD38? cell pool after 7 days of culture.
    Type: Application
    Filed: July 29, 2003
    Publication date: April 21, 2011
    Inventors: John P. Chute, Abba A. Saini, Dennis J. Chute, Thomas A. Davis
  • Patent number: 6642049
    Abstract: A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34+CD38− cells consistent with the PMVEC system is disclosed. HUBEC were isolated from cadaveric donors, passed in primary culture, cloned and found to be Von Willebrand Factor positive. Cultivation of purified bone marrow CD34+ cells on HUBEC monolayers supplemented with GM-CSF+IL-3+IL-6+SCF+flt-3 ligand caused a 14.5-fold increase in total cells, an 6.6-fold increase in CD34+ cells, and, most remarkably, a 440-fold increase in CD34+CD38− cells after 7 days. Further, CFU-GM production increased 15.1-fold, BFU-E increased 8-fold, and CFU-Mix increased 5.2-fold. Optimal generation was dependent upon the continued presence of exogenous supplied cytokines. Moreover, we found that non-brain human endothelial cells isolated from the same donors supported neither the expansion nor the maintenance of human CD34+CD38− cells.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: November 4, 2003
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: John P. Chute, Abha A. Saini, Dennis J. Chute, Thomas A. Davis